CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Clinical trials for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) trials appear
Sign up with your email to follow new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost immunotherapy for tough lung cancers
Disease control Recruiting nowThis study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels live longer or delay cancer growth. About 714 participants will receive either the combo or p…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:39 UTC